CENTOGENE announced today the opening of its first U.S. based rare disease laboratory in Cambridge, Massachusetts. The new facility, opening on August 1, 2018, will be the central point of contact for CENTOGENE’s collaboration partners that leverage its diagnostic services in the U.S.
CENTOGENE, driving the diagnostic workflows and individualized therapeutic decisions also in oncological setups is proud to host an inspiring meeting at the forefront of future therapeutic developments, a mini-symposium entitled „Patient-individualized vaccination in cancer“.
We are happy t announce that Richard Stoffelen, Chief Financial Officer of CENTOGENE, will present at the upcoming Jefferies 2018 Global Healthcare Conference, on June 8 at 8:00 a.m. ET in New York City.
CENTOGENE today announced that Dr. Arndt Rolfs, CEO and Founder of CENTOGENE, will present at the BIO International Convention, June 4-7, 2018 in Boston, MA.
CENTOGENE today announced that it has entered into an agreement with Aldeyra Therapeutics Inc., a biotechnology company developing next-generation medicines to improve the lives of patients with immune-mediated diseases.
Dr. Rolfs underlined the importance of transferring the rare disease diagnostics burden from the physicians’ shoulders in the laboratory environment.
CENTOGENE Announces Drug Development Collaboration with Orphazyme in Neuronopathic Gaucher Disease
CENTOGENE will make a formal presentation at the 19th Bio€quity Europe 2018 Conference to be held May 14-16, 2018 in Ghent, Belgium
CENTOGENE announces the Appointment of a New Supervisory Board Member, Bernd Modig
The 2nd annual Recent Advances in Rare Disease (RARD) conference, “Frequently Misdiagnosed Hereditary Disorders” will bring together worldwide experts, scientists and clinicians to discuss and exchange experiences, network and highlight the direction of the future development.
The study describes a retrospective study of GD patients undergoing treatment with ERT. Lyso-Gb1 levels were measured during patient follow-up visits, based on CENTOGENE’s dry blood spots filtercard (CentoCard®) technology, as well as other key indicators.
Dr. Ehlers will have overall responsibility for the company´s global and domestic operations, including processes and workflows for the entire genetic diagnostics business of the company. In addition, he will lead the company’s sales and marketing, legal and general administrative functions.
CENTOGENE´s Chief Financial Officer, Richard Stoffelen, is scheduled to present at the upcoming Cowen and Company 38th Annual Health Care Conference in Boston on Monday, March 12, 2018 at 12:00 p.m. Eastern Time.
There are more than 7,000 rare diseases where about 80% are hereditary. For most of the rare genetic diseases, knowledge is limited or not available at all. Read more about CENTOGENE’s initiative in unraring rare diseases on our website
Using next generation sequencing, we and our international partners were able to characterize new genetic variants in NKX6-2 cases. Find out more about the two key factors that have been influenced the research!
